Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
Immunovant, Inc. reported corporate updates and financial results for its fiscal first quarter ended June 30, 2026, centered on the development of IMVT-1402 across six autoimmune indications, including Graves’ disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjögren’s disease and cutaneous lupus erythematosus.
As of June 30, 2026, cash and cash equivalents were $797.8 million, which the company states provides runway to the potential commercial launch of IMVT-1402 in Graves’ disease based on its current operating plan. For the quarter, R&D expenses were $142.6 million, up from $101.2 million a year earlier, mainly from IMVT-1402 clinical and manufacturing activities, while G&A expenses declined to $17.7 million from $26.0 million. Net loss was $153.2 million, or $0.75 per share, versus $120.6 million, or $0.71 per share, in the prior-year quarter. Non-GAAP measures exclude $13.8 million of non-cash stock-based compensation. The company highlighted upcoming IMVT-1402 milestones, including D2T RA and CLE data in the second half of 2026, GD and MG topline data in 2027, and CIDP and Sjögren’s data in 2028.
Immunovant director Atul Pande exercised stock options for 1,500 shares of Common Stock at $8.43 per share and on the same date sold 1,500 shares at $39.80 per share. The option exercise involved a fully vested award and left 66,681 option shares outstanding. In addition, 20,000 Common Shares are held indirectly by a trust. All reported trades occurred under a Rule 10b5-1 trading plan adopted on December 26, 2025.
Immunovant, Inc. Chief Financial Officer Tiago Girao reported the sale of 6,798 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share. The mandated “sell to cover” transaction funded tax withholding on 13,024 vested RSUs, leaving him with 240,798 shares held directly.
Immunovant, Inc. reports that Chief Technology Officer Jay S. Stout sold 2,857 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share, with sale prices ranging from $38.18 to $39.05. The shares were sold to cover tax withholding obligations from the July 17, 2026 vesting of 6,250 restricted stock units from a 100,000-unit grant. After this mandated sell-to-cover transaction, he directly holds 205,341 shares of Immunovant common stock.
Immunovant, Inc. will hold its 2026 annual stockholders meeting virtually on September 2, 2026 at 1:00 p.m. Eastern Time. Holders of common stock and Series A preferred stock as of July 8, 2026 may vote on three items: electing directors Jacob Bauer, Douglas Hughes and Robert Susman; ratifying Ernst & Young LLP as independent auditor for the year ending March 31, 2027; and a non-binding advisory vote approving named executive officer compensation.
On the record date there were 206,402,338 common shares and 10,000 Series A preferred shares entitled to vote; Roivant Sciences Ltd. beneficially owned 54.9% of common stock and elects four of seven directors, making Immunovant a Nasdaq “controlled company” that uses certain governance exemptions while maintaining a fully independent three‑member Audit Committee. The proxy describes board structure, committee responsibilities, ownership detail, and a pay‑for‑performance executive compensation program using cash bonuses, options, RSUs, PSUs and CEO capped value appreciation rights.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported two open-market sales totaling 2,036 shares of common stock on July 8, 2026. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, under a mandated “sell to cover” arrangement rather than a discretionary trade.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported the disposition of 1,206 shares of common stock in open-market sales on July 8, 2026. According to the company’s description, these sales were executed under a mandatory “sell to cover” arrangement to satisfy tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, and were not discretionary trades.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported open-market sales totaling 3,487 shares of common stock on July 8, 2026. According to the footnotes, these trades were mandated “sell to cover” transactions to fund tax withholding triggered by the vesting and settlement of previously granted restricted stock units, rather than discretionary sales.
Immunovant, Inc. Chief Executive Officer Eric Venker reported a compensation-related equity transaction involving capped value appreciation rights (CVARs) and a small tax sale of common stock. On July 1, 2026, 92,188 vested CVARs were settled into shares of common stock after the service, performance, knock-in and hurdle price conditions were met. The same day, a Form 4 entry shows 86,629 shares of common stock disposed to the issuer at $38.14 per share. On July 2, 2026, he sold 3,092 shares of common stock at $38.48 per share in an open-market transaction, which the footnotes state was a mandatory “sell to cover” for tax withholding tied to the CVAR vesting rather than a discretionary sale. After these transactions, Venker directly holds 254,280 shares of Immunovant common stock.